The transaminase value of 670 U/L in patients after targeted therapy suggests seriousness of the disease, and the transaminase index is more than 5 times of the normal value, which indicates severe abnormalities of liver function, and discontinuation of targeted drugs is considered. Transaminases include ALT and AST, the normal value of ALT is <40U/L and the normal value of AST is <40U/L. In the course of treatment, symptomatic use of hepatoprotective drugs, mainly to give diammonium glycyrrhizinate or reduced glutathione treatment, after regular treatment, most of the patients alanine aminotransferase and glutamic oxalate aminotransferase can be restored to normal, and at the same time, patients should be weekly rechecking of liver function. If fatigue, anorexia, malaise, jaundice, etc. are found during the use of targeted drugs, they should be reported to the doctor in time and actively dealt with.